Apollon Wealth Management LLC Reduces Holdings in Solventum Corporation $SOLV

Apollon Wealth Management LLC reduced its holdings in shares of Solventum Corporation (NYSE:SOLV) by 6.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,789 shares of the company’s stock after selling 247 shares during the period. Apollon Wealth Management LLC’s holdings in Solventum were worth $287,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Rossby Financial LCC bought a new position in shares of Solventum in the first quarter worth approximately $25,000. Strengthening Families & Communities LLC lifted its holdings in shares of Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after buying an additional 260 shares in the last quarter. Barrett & Company Inc. grew its stake in Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares in the last quarter. Hara Capital LLC purchased a new position in shares of Solventum during the first quarter valued at about $38,000. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Solventum by 193.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after acquiring an additional 352 shares in the last quarter.

Solventum Stock Up 0.9%

NYSE:SOLV opened at $72.11 on Friday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The stock has a market capitalization of $12.50 billion, a P/E ratio of 33.38, a P/E/G ratio of 2.94 and a beta of 0.50. The company’s 50-day simple moving average is $72.63 and its 200-day simple moving average is $71.95. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $85.92.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the prior year, the firm posted $1.56 earnings per share. The business’s quarterly revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price target (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Solventum in a report on Wednesday, October 8th. Wells Fargo & Company boosted their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Wall Street Zen downgraded shares of Solventum from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Finally, Jefferies Financial Group started coverage on Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Solventum currently has a consensus rating of “Hold” and a consensus price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.